AbbVie Earnings Call Highlights Growth Amid Transition

Abbvie ((ABBV)) has held its Q1 earnings call. Read on for the main highlights of the call.

AbbVie’s latest earnings call struck an upbeat tone, with management emphasizing strong commercial momentum, a broad-based sales beat and a raise to full-year guidance. Executives highlighted double-digit growth across key immunology and neuroscience franchises, robust pipeline progress and sizable U.S. manufacturing investments, while acknowledging ongoing HUMIRA erosion, oncology and aesthetics pressures, and higher R&D-related expenses.

Quarterly Financial Beat and Guidance Raise

AbbVie posted adjusted EPS of $2.65, topping the guidance midpoint by $0.07, on total net revenues of $15.0 billion, roughly $300 million above expectations and up 12.4%. The company lifted full-year adjusted EPS guidance by $0.12 to a range of $14.08 to $14.28 and increased its full-year revenue outlook to about $67.3 billion, adding $300 million.

Strong Immunology Performance (Skyrizi & Rinvoq)

Immunology remained the growth engine, delivering $7.3 billion in revenue, up about $1.0 billion year over year. Skyrizi generated $4.5 billion in sales, up 29.2% operationally, and Rinvoq contributed $2.1 billion, up 20.2%, as Skyrizi gains share in psoriasis, psoriatic arthritis and inflammatory bowel disease with management targeting over 30% global IBD growth.

Neuroscience Momentum

Neuroscience revenues approached $2.9 billion, growing 24.3% operationally, underscoring AbbVie’s diversification beyond immunology. Vraylar delivered $905 million, rising 18.4%, while VYALEV reached $201 million with roughly 10% sequential growth, and the company is preparing for a potential U.S. launch of Parkinson’s therapy tavapadon later this year.

Selected Product Strengths and Category Leadership

Management underscored category leadership in key therapeutic and aesthetic segments, pointing to robust double-digit gains from Botox Therapeutic and its broader migraine portfolio. Botox Cosmetic sales reached $668 million, up 17%, while Skyrizi’s long-term data in psoriatic arthritis showed nearly 90% of patients without radiographic progression at five years and new labels for difficult psoriasis areas.

Pipeline Progress — Regulatory Submissions & Positive Readouts

The call highlighted pipeline momentum with several regulatory moves, including a U.S. filing for Rinvoq in alopecia areata. AbbVie also submitted Skyrizi’s subcutaneous induction for Crohn’s disease, with a decision expected later this year, and reported interim data on a Skyrizi plus ABBV-382 combination that suggested potentially transformational efficacy in Crohn’s.

Promising Early Obesity Data (ABBV-295)

AbbVie touted early obesity-related signals from ABBV-295, a long-acting amylin analog, in a multiple-ascending-dose study. The candidate produced nearly 10% weight loss over 12 weeks in a predominantly male, nonobese group with favorable tolerability and a half-life of about 270 hours, supporting future development with every-other-week or monthly dosing.

Oncology Pipeline Actions & External BD

In oncology, the company is leaning on business development and combination strategies to refresh its portfolio, including a deal with Remagen for a PD-1/VEGF bispecific asset. AbbVie is pivoting its Temab-A program toward combination with bevacizumab in colorectal cancer after early data showed an objective response rate near 30% and disease control around 97%, with more details expected around ASCO.

Capital Investment & Manufacturing Commitment

AbbVie detailed substantial capital plans as part of a broader U.S. R&D and investment pledge, including a $1.4 billion pharmaceutical campus in North Carolina. The company will also spend about $380 million on two plants in North Chicago to expand manufacturing capacity, reinforcing its confidence in long-term demand across key franchises.

Strong Profitability and Margin Targets

Profitability remained a focal point, with adjusted gross margin at 83.6% of sales and adjusted operating margin at 40.8% in the quarter, even after acquired in-process R&D. For the full year, AbbVie aims for an adjusted gross margin above 84% and an adjusted operating margin near 47.5%, framing the current quarter as a stepping stone toward higher margin levels.

Financial Flexibility & Capital Allocation

Financial flexibility improved as the company trimmed its adjusted net interest expense outlook to around $2.7 billion, about $100 million better than before. AbbVie reiterated its focus on record investment in the business, maintaining an active deal-making strategy and continuing to return cash to shareholders via a growing dividend.

HUMIRA Sales Decline from Biosimilars

The long-expected decline of HUMIRA continued, with global sales down 40.3% operationally to $688 million as biosimilars pressure the franchise. Management framed this erosion as a known headwind within its transition plan, emphasizing that growth from Skyrizi, Rinvoq and newer assets is offsetting the loss of legacy HUMIRA revenue.

Oncology and Specific Product Pressures

Total oncology revenue slipped to $1.6 billion, down 3% operationally, reflecting specific portfolio challenges. IMBRUVICA sales dropped 24.7% due to pricing dynamics under the IRA and heightened competition, though this was partially balanced by Venclexta, which grew 9.7% to $770 million.

Aesthetics Headwinds

Aesthetics delivered nearly $1.2 billion in revenue, up 5.1% operationally, but management acknowledged uneven performance within the segment. Juvederm sales declined 2.9% to $232 million amid continued dermal filler weakness in a tougher macro backdrop, compounded by a regulatory setback as one aesthetics application received a manufacturing-related FDA letter.

Clinical Setbacks and Non-Differentiation

The company also flagged some clinical disappointments, including ABBV-932 in bipolar depression, which failed to meet its primary endpoint overall despite a signal in bipolar I. Additionally, the Skyrizi plus lutikizumab combination did not show enough differentiation from Skyrizi alone and will be discontinued, underscoring AbbVie’s willingness to prune less compelling programs.

Pricing Pressure & Inventory Dynamics

Management noted that pricing remains a modest drag, with low-single-digit net price erosion expected across immunology for the year despite flat Skyrizi pricing in the first quarter. The quarter also included a modest inventory destocking effect, which the company framed as a temporary factor rather than a shift in underlying demand.

Acquired IPR&D Expense Impact

Acquired in-process R&D spending weighed on reported earnings, producing a $0.41 unfavorable EPS impact in the quarter. This spending shaved roughly five percentage points from the adjusted operating margin ratio, and while current guidance excludes future IPR&D beyond the first quarter, management emphasized these costs as part of a deliberate investment strategy.

Operational and Modeling Uncertainty in Some Programs

Investors were reminded that some key programs remain in early stages or hinge on future trial designs and regulatory interactions, particularly within oncology. This leaves execution and timing risk around anticipated readouts and approvals, which could influence how quickly pipeline assets begin to contribute meaningfully to revenue and earnings.

Aesthetic Market Uncertainty vs. Prior Cycles

Management contrasted the current aesthetics environment with prior downturns, noting that while toxins like Botox historically proved resilient, fillers are seeing more pressure this time. This suggests a slower recovery for certain aesthetic lines, prompting a more measured outlook for that segment even as the broader business continues to grow.

Forward-Looking Guidance and Outlook

AbbVie’s updated outlook calls for full-year net revenues of about $67.3 billion and second-quarter revenues near $16.7 billion, including a modest currency benefit, with Skyrizi, Rinvoq and neuroscience each nudged higher by $100 million. The company targets an adjusted operating margin around 47.5%, gross margin above 84%, adjusted R&D near $9.7 billion, SG&A around $14.2 billion and reduced net interest expense of $2.7 billion, framing a trajectory of rising earnings power.

AbbVie’s earnings call painted a picture of a company successfully navigating its post-HUMIRA transition, leveraging strong immunology and neuroscience growth to more than offset legacy headwinds. While oncology, aesthetics and certain pipeline setbacks remain watch points, the combination of a guidance raise, robust margin targets and visible capital deployment underpins a constructive outlook for investors focused on earnings durability and pipeline-driven upside.